UK markets open in 4 hours 41 minutes

Oncopeptides AB (publ) (0RN4.L)

LSE - LSE Delayed price. Currency in SEK
Add to watchlist
35.44-0.77 (-2.12%)
At close: 05:21PM BST
Currency in SEK

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) -0.61
52-week change 3-49.77%
S&P500 52-week change 321.08%
52-week high 337.83
52-week low 35.07
50-day moving average 37.16
200-day moving average 37.87

Share statistics

Avg vol (3-month) 31.19k
Avg vol (10-day) 3N/A
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 855.54M
% held by insiders 14.63%
% held by institutions 117.03%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,517.33%

Management effectiveness

Return on assets (ttm)-50.80%
Return on equity (ttm)-141.91%

Income statement

Revenue (ttm)35.22M
Revenue per share (ttm)0.39
Quarterly revenue growth (yoy)853.00%
Gross profit (ttm)N/A
EBITDA -251.44M
Net income avi to common (ttm)-249.11M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)173.41M
Total cash per share (mrq)1.83
Total debt (mrq)136.66M
Total debt/equity (mrq)240.69%
Current ratio (mrq)4.52
Book value per share (mrq)0.60

Cash flow statement

Operating cash flow (ttm)-279.49M
Levered free cash flow (ttm)-193.97M